BLA 021884 · Insmed
Iplex
Mecasermin Rinfabate Recombinant · Subcutaneous
NovelPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Feb 27, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Dec 12, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
5 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2005 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelOrphanLetterLabelReview
1 products under this application
- IPLEX · MECASERMIN RINFABATE RECOMBINANT 36MG/0.6ML · INJECTABLE, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Mecasermin Rinfabate Recombinant" as an intervention, any sponsor and status, largest first.
- Assessment of Mechanisms of Improved Wound HealingPivotal-lookingCompleted
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00673309 · 644 participants · Start Jul 2000 · Primary completion Apr 2011
Drug: Insulin High Dose; oxandrolone and 8 more · For: Burns
Sites: Galveston, Texas
- A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short StatureActive, not recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT03255694 · 360 participants (planned) · Start May 12, 2017 · Primary completion Jun 2030
Drug: PEG-somatropin · For: Dwarfism
Sites: Beijing, China; Wuhan, China; Changsha, China · 12 sites in all
- A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsPivotal-lookingActive, not recruiting
OHB Neonatology Ltd.Industry
NCT03253263 · 295 participants · Start May 9, 2019 · Primary completion Jul 31, 2026
Drug: OHB-607 · For: Bronchopulmonary Dysplasia; Chronic Lung Disease of Prematurity; Intraventricular Hemorrhage and 1 more
Sites: Little Rock, Arkansas; California City, California; Los Angeles, California · 62 sites in all
National Cancer Institute (NCI)NIH
NCT01016015 · 178 participants · Start Nov 2009 · Primary completion Jul 2014
Drug: Cixutumumab; Temsirolimus · For: Metastatic Osteosarcoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Osteosarcoma and 2 more
Sites: Los Angeles, California; Jacksonville, Florida; Tampa, Florida · 24 sites in all
- A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA InfantsStatus unknown
Tongji HospitalAcademic, hospital or other
NCT05144035 · 138 participants (planned) · Start Apr 6, 2022 · Primary completion Dec 31, 2025
Drug: PEG-rhGH · For: Small for Gestational Age Infant; Growth Hormone Treatment; Cognitive Developmental Disorder
Sites: Wuhan, China
- Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyPivotal-lookingCompleted
IpsenIndustry
NCT00125164 · 137 participants · Start Mar 2004 · Primary completion Jul 2008
Drug: rhIGF-1 (mecasermin, Tercica, Inc.) · For: Growth Disorders; Insulin-Like Growth Factor-1 Deficiency
Sites: Brisbane, California
- IGF-1/IGFBP3 Prevention of Retinopathy of PrematurityPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01096784 · 121 participants · Start Jun 18, 2010 · Primary completion Mar 30, 2016
Drug: rhIGF-I/rhIGFBP-3 · For: Retinopathy of Prematurity (ROP)
Sites: Mobile, Alabama; Irvine, California; Augusta, Georgia · 24 sites in all
- Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 DeficiencyPivotal-lookingTerminated
IpsenIndustry
NCT00330668 · 114 participants · Start Nov 2005 · Primary completion Feb 2010
Drug: rh IGF-1 (mecasermin) · For: Growth Disorders
Sites: Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- IL10 polymorphisms associated with Behçet's disease in Chinese Han.
Wu Z, Zheng W, Xu J, et al. · Hum Immunol 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study.
Orozco G, Eyre S, Hinks A, et al. · Ann Rheum Dis 2010 · Meta-Analysis, Multicenter Study
- Progressing Preemptive Genotyping of CYP2C19 Allelic Variants for Sickle Cell Disease Patients.
Jaja C, Barrett N, Patel N, et al. · Genet Test Mol Biomarkers 2016 · Clinical Trial
- Strategy to Estimate Sample Sizes to Justify the Association between MMP1 SNP and Osteoarthritis.
Kao CC, Hsu HE, Lai JC, et al. · Genes (Basel) 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Analysis and meta-analysis of five polymorphisms of the LINGO1 and LINGO2 genes in Parkinson's disease and multiple system atrophy in a Chinese population.
Chen Y, Cao B, Yang J, et al. · J Neurol 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A case-control study coupling with meta-analysis elaborates decisive association between IGF-1 rs35767 and osteoporosis in Asian postmenopausal females.
Su SL, Huang YH, Chen YH, et al. · Aging (Albany NY) 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Insmed
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.